Yahoo Finance

ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to ...

Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its ...
Yahoo Finance

ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Garden City, NY, Feb. 06, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today provided an ...
Nasdaq

ProPhase Labs, Inc. CEO Ted Karkus to Present at Q1 Investor Summit Virtual on March 11th

ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations and ...
Nasdaq

ProPhase Labs Inc. Receives 180-Day Extension from Nasdaq to Regain Bid Price Compliance

ProPhase Labs received a 180-day extension from Nasdaq to meet its $1.00 bid price compliance requirement. ProPhase Labs Inc. announced that it has received a 180-day extension from Nasdaq to meet the ...